Q3 2023 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2023-11-14 · accession 0001172661-23-004025
$549.0M
Reported value
42
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| M96088105 | URGN | UROGEN PHARMA LTD | $36.7M | 6.69% | 2,620,545 | Common | SHARED |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $35.3M | 6.42% | 3,078,633 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $30.4M | 5.54% | 1,755,184 | Common | SHARED |
| 92243G108 | PCVX | VAXCYTE INC | $27.1M | 4.93% | 531,211 | Common | SHARED |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $25.9M | 4.72% | 727,426 | Common | SHARED |
| G01767105 | ALKS | ALKERMES PLC | $24.5M | 4.46% | 875,044 | Common | SHARED |
| 75382E109 | — | RAPT THERAPEUTICS INC | $24.2M | 4.41% | 1,458,070 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $21.7M | 3.96% | 3,295,000 | Common | SHARED |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $20.0M | 3.65% | 165,200 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $20.0M | 3.64% | 2,186,934 | Common | SHARED |
| 730541109 | — | POINT BIOPHARMA GLOBAL INC | $19.4M | 3.54% | 2,909,960 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC | $17.7M | 3.22% | 600,000 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $17.1M | 3.11% | 500,001 | Common | SHARED |
| 032724106 | ANAB | ANAPTYSBIO INC | $16.1M | 2.93% | 894,333 | Common | SHARED |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $15.1M | 2.75% | 290,917 | Common | SHARED |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $14.8M | 2.70% | 1,091,233 | Common | SHARED |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $11.7M | 2.13% | 225,000 | Common | SHARED |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $11.6M | 2.11% | 1,691,768 | Common | SHARED |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $11.5M | 2.10% | 95,000 | PUT | SHARED |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $11.2M | 2.04% | 500,000 | Common | SHARED |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $10.9M | 1.99% | 638,495 | Common | SHARED |
| 68404V100 | — | OPTINOSE INC | $10.9M | 1.98% | 8,839,939 | Common | SHARED |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $10.4M | 1.90% | 857,000 | Common | SHARED |
| 03940C100 | ACLXGBX | ARCELLX INC | $10.3M | 1.88% | 287,500 | Common | SHARED |
| 48576A100 | — | KARUNA THERAPEUTICS INC | $10.2M | 1.86% | 60,500 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $10.0M | 1.83% | 198,500 | Common | SHARED |
| 457669307 | INSM | INSMED INC | $10.0M | 1.82% | 394,872 | Common | SHARED |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $8.9M | 1.62% | 1,167,061 | Common | SHARED |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $8.5M | 1.55% | 400,000 | Common | SHARED |
| 38341P102 | GOSS | GOSSAMER BIO INC | $5.2M | 0.95% | 6,230,272 | Common | SHARED |
| 449585108 | 1K0 | IGM BIOSCIENCES INC | $5.1M | 0.94% | 615,317 | Common | SHARED |
| 427746102 | HRTX | HERON THERAPEUTICS INC | $4.9M | 0.89% | 4,737,368 | Common | SHARED |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $4.8M | 0.87% | 700,000 | CALL | SHARED |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $4.7M | 0.85% | 215,000 | Common | SHARED |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $4.5M | 0.81% | 1,074,101 | Common | SHARED |
| 37148K100 | GBIOGBX | GENERATION BIO CO | $3.9M | 0.71% | 1,022,537 | Common | SHARED |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $3.8M | 0.68% | 86,302 | Common | SHARED |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $3.2M | 0.59% | 645,899 | Common | SHARED |
| 87410C104 | — | TALARIS THERAPEUTICS INC | $2.8M | 0.51% | 1,000,000 | Common | SHARED |
| 38406L103 | — | GRACELL BIOTECHNOLOGIES INC | $1.7M | 0.30% | 579,667 | Common | SHARED |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $1.1M | 0.21% | 450,403 | Common | SHARED |
| 02290A102 | — | AMBRX BIOPHARMA INC | $1.1M | 0.20% | 97,700 | CALL | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.